Back to results
US 12,569,575 B2Granted
Radiopaque particle compositions and uses thereof
AssigneeGustave Roussy Transfert
InventorsAMi Mehta, Anup Dasnurkar
Life of this patent
Estimating the term…
Abstract
Compositions and emulsions are described, which are useful in treating disease.
Claims16
An emulsion, comprising a composition comprising:
- a pharmaceutical ingredient;
- a component of poppy seed oil selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, myristic acid, heptadecanoic acid, arachidic acid, γ-tocopherol, a glyceride and combinations thereof;
- and
- a biodegradable radiopaque polymeric particle comprising a visualization agent and:
- PLGA monomer;
- PLLA monomer;
- PLLA monomer and PLA monomer;
- PEG diacrylamide monomer, glycerol monomethacrylate monomer, 2-amino ethyl methacrylate monomer, and N,N-methylenebisacrylamide monomer;
- PEG diacrylamide monomer, amino propyl methacrylamide monomer, and 3-sulfopropyl acrylate potassium salt monomer;
- or PCL monomer and gelatin,
- wherein the pharmaceutical ingredient is axitinib, bosutinib, cabozantinib, canertinib, dasatinib, dovitinib, doxorubicin, epirubicin, erlotinib, gefitinib, gemcitabine, idarubicin, imatinib, lapatinib, lestaurtinib, lenvatinib, masitinib, nilotinib, pazopanib, regorafenib, sorafenib, sunitinib, terazosin, vandetanib, vatalanib, oxaliplatin, or carboplatin, or a pharmaceutically acceptable salt thereof,
- wherein the visualization agent is an iodinated compound, barium sulfate, superparamagnetic iron oxide, or a gadolinium molecule, or a combination thereof, and
- wherein the visualization agent has a concentration of about 5% to about 65% by weight.
10 more elements
A Pickering emulsion comprising a composition comprising:
- a pharmaceutical ingredient;
- a component of poppy seed oil selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, myristic acid, heptadecanoic acid, arachidic acid, γ-tocopherol, a glyceride and combinations thereof;
- and
- a biodegradable radiopaque polymeric particle comprising a visualization agent and:
- PLGA monomer;
- PLLA monomer;
- PLLA monomer and PLA monomer;
- PEG diacrylamide monomer, glycerol monomethacrylate monomer, 2-amino ethyl methacrylate monomer, and N,N-methylenebisacrylamide monomer;
- PEG diacrylamide monomer, amino propyl methacrylamide monomer, and 3-sulfopropyl acrylate potassium salt monomer;
- or PCL monomer and gelatin,
- wherein the pharmaceutical ingredient is axitinib, bosutinib, cabozantinib, canertinib, dasatinib, dovitinib, doxorubicin, epirubicin, erlotinib, gefitinib, gemcitabine, idarubicin, imatinib, lapatinib, lestaurtinib, lenvatinib, masitinib, nilotinib, pazopanib, regorafenib, sorafenib, sunitinib, terazosin, vandetanib, vatalanib, oxaliplatin, or carboplatin, or a pharmaceutically acceptable salt thereof,
- wherein the visualization agent is an iodinated compound, barium sulfate, superparamagnetic iron oxide, or a gadolinium molecule, or a combination thereof, and
- wherein the visualization agent has a concentration of about 5% to about 65% by weight.
10 more elements
Dependencies are inferred from the claim text.